Medical Condition News

RSS

Medical researchers race to find ways to use gene sequencing to fight cancer

Technology is quickly revamping medical care. The New York Times looks at the possible use of gene sequencing, while other news outlets examine apps and online tools that are helping Alzheimer's and autism caregivers.

23 Apr 2013

Cystic Fibrosis Foundation issues statement on Phase 2 clinical trial of Kalydeco, VX-661

The Cystic Fibrosis Foundation issued the following statement in response to an announcement by Vertex Pharmaceuticals Inc. regarding promising results from a Phase 2 clinical trial of its cystic fibrosis drug Kalydeco in combination with another potential CF therapy, VX-661.

23 Apr 2013

NKI-AVL joins research consortium to develop MRI-guided radiation therapy system for cancer care

Elekta and Royal Philips Electronics announced today that The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital has signed an agreement to join a research group to advance the development of ground-breaking image-guided treatment technology for cancer care.

From Elekta 23 Apr 2013

Pergamum reaches LPLV in Phase I/II trial of LL-37 for treatment of hard-to-heal venous leg ulcers

Pergamum AB announced today that the company has reached last-patient-last-visit in a randomized Phase I/II trial of LL-37 for the treatment of hard-to-heal venous leg ulcers. Karolinska Development AB is the majority owner of Pergamum.

23 Apr 2013

Enrollment for Pharmacyclics' Phase III study using ibrutinib in CLL patients completed

Pharmacyclics, Inc. announced today that the enrollment target of 350 patients for its Phase III study using ibrutinib monotherapy versus ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia / small lymphocytic lymphoma, (RESONATE) was achieved on April 3, 2013.

23 Apr 2013

Alkermes reports topline results from phase 2 study of ALKS 5461 drug for major depressive disorder

Alkermes plc (NASDAQ: ALKS) today announced positive preliminary topline results from a phase 2 study of ALKS 5461, its novel drug compound for major depressive disorder (MDD) in patients who have an inadequate response to standard therapies for clinical depression.

22 Apr 2013

Aeterna enters into agreements to transfer manufacturing license for Cetrotide to Merck KGaA

Aeterna Zentaris Inc. today announced that its German subsidiary has entered into binding agreements with various partners and licensees with respect to the manufacturing rights and obligations for its Cetrotide® product.

22 Apr 2013

UB researchers develop aniontransporters to trigger cancer cell apoptosis

The journal Accounts of Chemical Research, which has a profound impact on Chemistry and other related sciences, publishes on its current issue the article "Anion Transporters and Biological Systems", signed by Professor Ricardo Pérez Tomás, from the Department of Pathology and Experimental Therapy of the Faculty of Medicine at the University of Barcelona, Roberto Quesada, from the Department of Chemistry of the Sciences Faculty at the University of Burgos, and Philip A. Gale, from the University of Southampton, in the United Kingdom.

22 Apr 2013

Discovery reverses the prevailing model of how dividing cells monitor equal distribution of chromosomes

Ludwig researchers Arshad Desai and Christopher Campbell, a post-doctoral fellow in his laboratory, were conducting an experiment to parse the molecular details of cell division about three years ago, when they engineered a mutant yeast cell as a control that, in theory, had no chance of surviving. Apparently unaware of this, the mutant thrived.

22 Apr 2013

American College of Surgeons grants Outstanding Achievement Award to 79 accredited cancer programs

The Commission on Cancer (CoC) of the American College of Surgeons (ACS) has granted its 2012 Outstanding Achievement Award to a select group of 79 accredited cancer programs throughout the United States.

22 Apr 2013

Two views are necessary in 3D breast screening to ensure cancer is optimally visualized

One view 3D breast screening (tomosynthesis) means less radiation dose and about five seconds less compression, but a study from Yale University, New Haven, CT, found that obtaining both views is necessary to help ensure that a cancer won't be missed.

22 Apr 2013

Single puncture technique safe and effective in intravascular ultrasound-guided inferior vena cava filter placement

One venous puncture, rather than two, is a safe and effective approach to intravascular ultrasound-guided inferior vena cava filter placement in critically-ill patients, a new study shows.

22 Apr 2013

Study: Image-guided brachytherapy prevents growth of cervical tumour in over 90% of patients

Two large, landmark radiotherapy studies have shown that it is possible to treat cervical cancer effectively with high doses specifically adapted to each tumour, and with fewer serious side-effects to the surrounding normal organs.

22 Apr 2013

Researchers suggest two days of staging at moderate altitude reduces acute mountain sickness

Afghanistan's geography is dominated by a collection of craggy peaks, the highest-a mountain known as Noshaq-has been measured to 7,492 meters. Consequently, the soldiers on duty in this mountainous terrain must often ascend to great heights as part of their duty.

22 Apr 2013

Advances in treatment have improved the chances of survival for young patients with cancer

Over the years, advances in treatment have improved the chances of survival for young patients with cancer. But long-term survivors need to be aware of cancer treatments that may place them at increased risk of heart disease later in life.

22 Apr 2013

Cerecor obtains exclusive, worldwide rights to NR2B receptor antagonist from Merck

Cerecor Inc, a neuroscience biotech company that develops therapies that have the potential to make a difference in diseases with high unmet medical needs, today announced that it has acquired exclusive, worldwide rights from Merck, known as MSD outside the United States and Canada, to develop and commercialize MK-0657, a small molecule NMDA receptor subunit 2B (NR2B) antagonist for all human indications, including depression.

22 Apr 2013

Advaxis completes ADXS-HPV Phase 1/2 dosing in patients with HPV-associated anal cancer

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that the first patient has been dosed in a Phase 1/2 study of ADXS-HPV in 25 patients with HPV-associated anal cancer coordinated by the Brown University Oncology Research Group (BrUOG).

22 Apr 2013

Advaxis to license its ADXS-HPV product candidate to FusionVax

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that it has entered into a Memorandum of Understanding (MoU) with FusionVax, Inc. ("FusionVax") setting forth the main terms under which Advaxis will, subject to the entry of a definitive agreement, exclusively license its lead clinical stage product candidate, ADXS-HPV, to FusionVax for Asia.

22 Apr 2013

Clinical Research Forum selects sickle cell project among 'Top 10' clinical research achievements of 2012

Pioneering research led by Johns Hopkins scientists on the use of partially matched bone marrow transplants to wipe out sickle cell disease has been selected as one of the Top 10 Clinical Research Achievements of 2012 by the Clinical Research Forum.

22 Apr 2013

Synta completes GALAXY-2 trial evaluating ganetespib inhibitor in non-small cell lung cance

Synta Pharmaceuticals Corp. announced today that the first patients have been treated in the randomized GALAXY-2 Phase 3 trial designed to evaluate docetaxel plus ganetespib, its investigational Hsp90 inhibitor, versus docetaxel alone for the second-line treatment of non-small cell lung adenocarcinoma.

22 Apr 2013

Medical Condition News

Medical researchers race to find ways to use gene sequencing to fight cancer

Cystic Fibrosis Foundation issues statement on Phase 2 clinical trial of Kalydeco, VX-661

NKI-AVL joins research consortium to develop MRI-guided radiation therapy system for cancer care

Pergamum reaches LPLV in Phase I/II trial of LL-37 for treatment of hard-to-heal venous leg ulcers

Enrollment for Pharmacyclics' Phase III study using ibrutinib in CLL patients completed

Alkermes reports topline results from phase 2 study of ALKS 5461 drug for major depressive disorder

Aeterna enters into agreements to transfer manufacturing license for Cetrotide to Merck KGaA

UB researchers develop aniontransporters to trigger cancer cell apoptosis

Discovery reverses the prevailing model of how dividing cells monitor equal distribution of chromosomes

American College of Surgeons grants Outstanding Achievement Award to 79 accredited cancer programs

Two views are necessary in 3D breast screening to ensure cancer is optimally visualized

Single puncture technique safe and effective in intravascular ultrasound-guided inferior vena cava filter placement

Study: Image-guided brachytherapy prevents growth of cervical tumour in over 90% of patients

Researchers suggest two days of staging at moderate altitude reduces acute mountain sickness

Advances in treatment have improved the chances of survival for young patients with cancer

Cerecor obtains exclusive, worldwide rights to NR2B receptor antagonist from Merck

Advaxis completes ADXS-HPV Phase 1/2 dosing in patients with HPV-associated anal cancer

Advaxis to license its ADXS-HPV product candidate to FusionVax

Clinical Research Forum selects sickle cell project among 'Top 10' clinical research achievements of 2012

Synta completes GALAXY-2 trial evaluating ganetespib inhibitor in non-small cell lung cance

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News